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ABSTRACT
Objectives: Respiratory infections are responsible for
a large global burden of disease. We assessed the
public and philanthropic investments awarded to UK
institutions for respiratory infectious disease research
to identify areas of underinvestment. We aimed to
identify projects and categorise them by pathogen,
disease and position along the research and
development value chain.
Setting: The UK.
Participants: Institutions that host and carry out
infectious disease research.
Primary and secondary outcome measures:
The total amount spent and number of studies with a
focus on several different respiratory pathogens or
diseases, and to correlate these against the global
burden of disease; also the total amount spent and
number of studies relating to the type of science, the
predominant funder in each category and the mean
and median award size.
Results: We identified 6165 infectious disease studies
with a total investment of £2·6 billion. Respiratory
research received £419 million (16.1%) across 1192
(19.3%) studies. The Wellcome Trust provided greatest
investment (£135.2 million; 32.3%). Tuberculosis
received £155 million (37.1%), influenza £80 million
(19.1%) and pneumonia £27.8 million (6.6%). Despite
high burden, there was relatively little investment in
vaccine-preventable diseases including diphtheria (£0.1
million, 0.03%), measles (£5.0 million, 1.2%) and
drug-resistant tuberculosis. There were 802 preclinical
studies (67.3%) receiving £273 million (65.2%), while
implementation research received £81 million (19.3%)
across 274 studies (23%). There were comparatively
few phase I–IV trials or product development studies.
Global health research received £68.3 million (16.3%).
Relative investment was strongly correlated with 2010
disease burden.
Conclusions: The UK predominantly funds preclinical
science. Tuberculosis is the most studied respiratory
disease. The high global burden of pneumonia-related
disease warrants greater investment than it has
historically received. Other priority areas include
antimicrobial resistance (particularly within
tuberculosis), economics and proactive investments for
emerging infectious threats.
INTRODUCTION
Respiratory infections are responsible for a
large global burden of disease, with lower
respiratory tract infections accounting for
115 227 000 disability-adjusted life years
(DALYs) in 2010.1 Worldwide each year, there
are an estimated 120 million pneumonia epi-
sodes and 1.2 million deaths, with 72% of
these deaths in children aged under 2 years—
and the vast majority of cases and mortality
occurring in south-east Asia and Africa.2
Tuberculosis also represents a substantial
challenge to global health, accounting for
2.2% of all-cause DALYs lost worldwide,1 and
an estimated 1.4 million deaths in 2011.3
Control efforts are hampered by limited
vaccine effectiveness, coinfection with HIV,
insufﬁcient diagnostic capacity in low-income
settings, prolonged treatment courses and
the emergence of drug-resistant strains.3 4
Globally, an estimated 500 000 deaths
annually are attributable to inﬂuenza.5 Viral
reassortment can lead to novel strains with
Strengths and limitations of this study
▪ This is the first study that analyses public and
philanthropic investments awarded to UK institu-
tions for respiratory infectious disease research
to identify areas of underinvestment.
▪ Our results highlight clear gaps in the UK
research portfolio and illustrate some priority
areas for funders and policymakers.
▪ We also highlight the strengths in preclinical
research in the UK.
▪ We do not have private sector data, and their
contributions to areas such as diagnostics and
vaccine development are currently unknown.
Further international data are required to assess
the true research gaps related to global respira-
tory infectious disease investments.
▪ Categorising is subjective, and we do not take
into account funding of overheads or the impact
of the introduction of full economic costing.
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pandemic potential, such as H1N1pdm09 strain which
emerged in Mexico in 2009 and rapidly spread world-
wide. This strain remained the dominant inﬂuenza
strain across Europe in 2013, and the emerging H7N9
strain provides further cause for immediate concern.6
Severe acute respiratory syndrome (SARS) arose in
China in 2002 and rapidly caused over 8000 cases with
case fatality rate of almost 10%,7 and the emergence in
2013 of the Middle East respiratory syndrome corona-
virus has caused global concern.8
Respiratory Syncytial Virus (RSV) is estimated to cause
each year 33 million new episodes of acute lower respira-
tory tract infection worldwide in children younger than
5 years, and up to an estimated 199 000 deaths per year
—almost all of which are in low-income settings.9 The
variable coverage of the measles, mumps and rubella
vaccine is well documented,10 and measles is still respon-
sible for considerable disease burden globally (14.8
million DALYs in 2010).1 Pertussis has received media
coverage in high-income countries,11 and respiratory
infections have elsewhere been implicated in the aeti-
ology of chronic respiratory diseases, such as asthma,12
chronic obstructive pulmonary disorder13 and cystic
ﬁbrosis,14 as well as acting as a trigger for acute cardio-
vascular events.15
UK institutions have received an estimated £2.6 billion
of public and charitable funding to carry out infectious
disease research between 1997 and 2010,16 and accord-
ing to estimates from Policy Cures, the UK ranks second
globally in terms of the amount of research and develop-
ment (R&D) funding for infectious disease research.17
Funding covers all types of science along the R&D value
chain from preclinical to operational and implementa-
tion research. We report on the funding for respiratory
infection-related research awarded to UK institutions.
We identify areas of research strength and possible
investment gaps in relation to respiratory global health
that will be of relevance to policy-makers, funders and
researchers, and brieﬂy discuss how new approaches
might help with allocating the existing resources and
identifying new sources of investment.
METHODS
We analysed studies funded over a 14-year period
(1997–2010 inclusive) and identiﬁed those relevant to
respiratory infectious disease. Global health studies were
deﬁned as those which investigated diseases not endemic
in the UK, or where the study had a clear reference to
another country (eg, tuberculosis in South Africa). The
pneumonia category included preclinical studies for
Streptococcus pneumoniae and Haemophilus inﬂuenzae. We
excluded open-access data from the pharmaceutical
industry as it was limited and not representative.
The methods have been described in detail previ-
ously.18 The overarching dataset was constructed by
approaching the major sources of public and charitable
funding for infectious disease research studies, including
the Wellcome Trust, Medical Research Council and
other research councils, UK government departments,
the European Commission, Bill and Melinda Gates
Foundation and other research charities (ﬁgure 1).
Where feasible, the funding decisions listed on their
website were searched for infectious disease research
awards (eg, Wellcome Trust); otherwise, the funder was
directly approached and asked to provide information
on their infection-related awards. Other databases were
also searched, including Clinicaltrials.gov and the
National Research Register.
Each study was screened for relevance to infectious
disease research and assigned to as many primary
disease categories as appropriate.19 Within each cat-
egory, topic-speciﬁc subsections (including speciﬁc
pathogen or disease) were documented. Studies were
also allocated to one of four categories along the R&D
value chain: preclinical; phase 1, 2 or 3; product devel-
opment; and implementation and operational
research.19 Funders were either considered in their own
right, or were grouped into categories, such as in-house
university funding, research charities and government
departments. A total of 26 funder categories were
used.19 This categorisation was carried out by author
MGH, with provisional datasets circulated to authors for
review and comment, and JRF, MKC and FBW further
veriﬁed a random sample of 10% of the dataset, with
author agreement measured by a κ score (0.95) and dif-
ferences settled by consensus. We excluded studies not
immediately relevant to infection, veterinary infectious
disease research studies (unless there was a clear
zoonotic component) and studies where there were UK
collaborators, but the funding was awarded to a non-UK
institution. Unfunded studies were also excluded. Grants
awarded in a currency other than pounds sterling were
converted to UK pounds using the mean exchange rate
in the year of the award. All awards were adjusted for
inﬂation and reported in 2010 UK pounds. Relative
levels of investment were presented via a ‘£ per DALY’
ﬁgure; this represented the total investment in research
per one DALY. The DALY ﬁgures were extracted from
the Global Burden of Disease study.1
We used fold differences and statistical tests (non-
parametric Mann-Whitney rank sum test, K-sample test
and non-parametric Wilcoxon signed-rank test) to
compare total investment, number of studies, mean
grant and median grant according to speciﬁc infection,
disease system, funding organisation and cross-cutting
categories. Associations between disease burden and
research investment were assessed using Spearman’s
rank correlation coefﬁcient (r). A value greater or equal
to 0.7 was considered strongly correlated, greater or
equal to 0.40 and less than 0.70 was considered
moderately correlated and a value under or equal to
0.40 was considered poorly correlated. Data manage-
ment was carried out in Microsoft Excel and Access
(versions 2000 and 2007) and statistical analysis with
Stata (V.11).
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RESULTS
From a total of 325 922 studies screened, we identiﬁed
6165 studies that met the inclusion criteria with a total
investment of £2.6 billion. Of the 6165 studies, 1192
were identiﬁed as relevant to respiratory infection
research with a total funding of £418.8 million, mean
study funding of £351 375 (SD £661 990) and median
funding of £158 966 (IQR £50 203–£342 049).
Preclinical science received £273.0 million (65.2% of
total respiratory funding) across 802 studies, phase I–III
trials £23·6 million (5.6%) across 35 studies, product
development research £41.2 million (9.8%) across 81
studies and implementation and operational research
£81.0 million (19.3%) across 274 studies (see online
supplementary data). There was no clear temporal trend
in funding awards (ﬁgure 2). Global health-related
studies received £68.3 million (16.3%) across 117 studies
(9.8%; across all infectious disease, studies with a clear
global health component represented 35.6% of all
funding).18
Figure 1 Flowchart of study methodology.
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By disease (table 1), tuberculosis received £155.3
million across 329 studies, inﬂuenza £80.1 million across
141 studies and pneumonia £27.8 million across 102
studies. Preclinical science received the most investment
in these disease areas (tuberculosis 57.8%, inﬂuenza
72.3% and pneumonia 87.5%, see online supplementary
data). Other respiratory diseases received substantially
less funding, and investments were heavily concentrated
within preclinical science—for example, RSV (total
£16.9 million of which 80.3% was preclinical) and
Pseudomonas research (total £6.5 million, preclinical
90.3%). The sum of coronavirus research covered just
six studies, all of them being preclinical. Research relat-
ing to infections in chronic respiratory disease (mostly
cystic ﬁbrosis, chronic obstructive pulmonary disorder
and asthma) totalled £8.9 million across 57 studies.
Table 2 provides the breakdown of funding for other
selected disciplines of importance, and here reported
speciﬁc to respiratory infectious disease. Vaccine-related
studies received £51.9 million across 151 studies with
£19.1 million for tuberculosis and £10.9 million for
inﬂuenza vaccine research. Therapeutics-related
research received £39.3 million, with £21.5 million for
tuberculosis and £1.6 million for inﬂuenza research.
Diagnostics-related research received £18.0 million, with
£10.0 million to tuberculosis and £5.6 million for inﬂu-
enza diagnostics. Furthermore, there were 43 studies
totalling £14.5 million on antimicrobial resistance, 49
studies totalling £10.2 million on primary care research
and 76 studies totalling £21.7 million relating to paediat-
rics. Health economics and cost-effectiveness studies
received funding of £1.7 million.
By funder, the Wellcome Trust invested the greatest
amount for respiratory infection research (£126.9
million, 33.5%), followed by the Medical Research
Council (£116.4 million, 30.7%). The Wellcome Trust
provided most of the investment for tuberculosis
research and cross-cutting themes including vaccinology,
therapeutics and global health. The MRC was the top
Figure 2 Investments on respiratory infection research
awarded to the UK over time and by type of science.
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funder for inﬂuenza, and the European Commission
was the top funder for diagnostics.
Where data are available, the global burden of
disease in DALYs was correlated with levels of research
investment (ﬁgure 2, table 3); using 2004 DALYs as the
mid-point of the study timeframe, there is an overall
investment of £4.28 per DALY for respiratory infections
as a whole and £4.54 per DALY for tuberculosis, with
relatively less investment for measles (£0.34), pertussis
(£0.25) and diphtheria (£0.81). Relative investment in
respiratory infectious diseases was strongly correlated
with disease burden (DALYs) in 2010 (Spearman’s
r 0.8571, p=0.0625). Pneumonia is arguably, currently,
the most neglected respiratory discipline in terms of
R&D investment, with the UK demonstrating relatively
greater investments in inﬂuenza and tuberculosis
(ﬁgure 3). Changes in investment between 1997–2004
and 2005–2010 show that tuberculosis, inﬂuenza and
pneumonia have received greater focus in the later
time period (ﬁgure 4).
DISCUSSION
Our study is the ﬁrst systematic analysis of research
funding for respiratory infections research. We quantify
research funding for preclinical science and transla-
tional types of research, with relatively little amount
spent on phase 1–3 clinical trials and product develop-
ment studies. Over half of the research funding was for
tuberculosis and inﬂuenza. Vaccine development and
global health studies form a key part of the UK research
output, although there is proportionately less global
health research within respiratory infectious disease
than across all infectious disease. During this study
period, there were increases in inﬂuenza research
funding but very limited funding for emerging infec-
tions such as coronaviruses. There is some evidence of
increased funding over time, although sum funding per
annum is unpredictable, and the decline since 2008 may
reﬂect global economic conditions. Tuberculosis, inﬂu-
enza and pneumonia received increased investment in
2005–2010 as compared with 1997–2004; this may be
due to a more systematic approach to collecting burden
data, and thus translating into R&D investments. The
focus on inﬂuenza will likely have been at least in part
due to the highlighting of emerging strains with pan-
demic potential. The strong correlation between burden
and investment is encouraging with, broadly, the high-
burden diseases receiving greater funding (pneumonia
being the key exception), and lower-burden infections
less funding. Within therapeutics research, the propor-
tionately greater investment for tuberculosis compared
with inﬂuenza seems appropriate, as does the
tuberculosis-related focus within diagnostics.
New high-impact infection threats to humans are
often related to respiratory systems. From SARS to inﬂu-
enza to Middle East respiratory syndrome, these have
the potential to be highly virulent with rapid
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transmission and global spread, and with substantial
health and economic impact. Although difﬁcult to
accurately quantify, in our dataset there was little
funding for research to develop predictive epidemio-
logical models for future pandemics—which would be
an important part of infection prevention and control.
However, caution must be exercised when developing
these epidemiological models using limited datasets.20
Investment for data collection, predictive modelling
(with analysis of health and economic impact with and
without interventions) should be a priority for funders,
along with investments in preclinical science and clinical
trials. The lack of investment for coronavirus-related
research across all types of science is particularly con-
cerning (though some surveillance and research in
response to outbreaks will not necessarily receive formal
funding, and thus may not be captured by our analysis).
The 2011 Pseudomonas outbreak and deaths in a neo-
natal unit in Northern Ireland21 further highlight the
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Figure 3 Research and Development investment correlated
with burden of disease (2010 disability-adjusted life year).
Figure 4 Changes in investment for respiratory infectious
diseases between time period 2005–2010 and 1997–2004.
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need for research for prevention of nosocomial out-
breaks related to respiratory infectious disease.
There was limited funding for pneumococcal and
pneumonia research. While infections such as meningi-
tis may be in decline in some countries due to successful
introduction of new vaccines,22 there are still many areas
globally with weak health systems where pneumococcal
incidence is high. There is also evidence of respiratory
infection transmission at mass gatherings, such as the
Hajj.23 In addition to providing meningococcal and
inﬂuenza vaccination for travellers, there should be
investment in operational research to explore health
system responsiveness to emerging threats and efﬁcient
ways to provide preventive medicines, as well as measur-
ing the effectiveness of preventive therapies. There was
very little funding for translational research relating to
pneumonia, a clear gap in the UK portfolio. Other
vaccine-preventable diseases such as measles and pertus-
sis, which are causes of high disease burden globally,
also received very limited research funding despite there
clearly being the need for translational and operational
research.16
The worldwide burden of drug-resistant tuberculosis is
rapidly increasing, with WHO estimates of 630 000 cases
of multidrug-resistant tuberculosis worldwide, great vari-
ation between countries and emergence over the last
decade of extensively drug-resistant cases.24 Given the
difﬁculties of developing a more effective vaccine,25 the
need for new diagnostics, therapeutics and targeted use
of existing medicines becomes even more important.
The reported resistance to antiviral drugs used to treat
inﬂuenza26 emphasises the need to develop effective
antivirals and effective vaccines. There is a paucity of
research in antimicrobial resistance.27 This is of
concern, and has been highlighted by the UK Chief
Medical Ofﬁcer,28 29 with new funding for research
related to antimicrobial resistance provided.30 We
believe that other funders should follow this lead. Most
countries are underinvesting in tuberculosis R&D31
which requires additional investment if drug-resistant
tuberculosis is to be contained.
The different ‘top funder’ for each individual disease
or pathogen highlights the importance of maintaining
access to a diverse group of funding institutions.
Collaborations with the private sector are urgently
required in vaccine development, therapeutics and diag-
nostics, but there is evidence that where public sector
investment decreases, so does private investment.32 New
and novel sources of investment, possibly from philan-
thropic or governmental bodies, would help with the
focus on priority areas, particularly given that a reduction
in public funding can coincide with reductions in private
sector investment.32 Resources such as the Sovereign
Wealth Funds belonging to individual nations could be
utilised.33 It should also be noted that considerations
other than incidence should ultimately inﬂuence the
allocation of resources. Such considerations may include
the prevalence and predicted impact of the disease, how
treatable the disease is (antibiotic courses and combina-
tions are very different between pneumonia and tubercu-
losis), cofactors and comorbities (eg, tuberculosis and
coinfection with HIV), consideration of how other types
of research may impact and inform the issues of control-
ling spread of respiratory infectious disease (eg, basic
immunology research may eventually inform future
vaccine development) and anticipation of future new
tools, technologies or research methods. There must also
be a supply line of individuals who are sufﬁciently skilled
and motivated to carry out the research.
Our study has several limitations, which have been
highlighted and discussed in detail elsewhere.16 There
were little publicly available data from the pharmaceut-
ical industry. Hence, there is a data gap in relation to
funding of clinical trials and development of vaccines
and diagnostics, which the pharmaceutical and biotech-
nology industry are ﬁnancing. Beyond disease burden,
other measures, such as economic burden, should also
be utilised when prioritising limited resources, but little
information is available regarding the economic impact
of respiratory infections. We rely on the original data
being complete and accurate, and are unable to take
into account distribution of funds from the lead institu-
tion to collaborating partners, nor can we assess quantity
of each award given to overheads or the impact of the
introduction of full-economic costing. Also, assigning
studies to categories is a subjective and imperfect
process—although we used two researchers to do this to
reduce interobserver error. Our study focuses on UK-led
investments—we do not know whether similar patterns
(eg, a dominance of preclinical research and lack of
public or charitably funded clinical trials) would also
emerge if the analysis were repeated for other high-
income countries. We have not measured either the
outputs or impact of funded research. The assessment
against measures of burden used the most comprehen-
sive DALY ﬁgures available, but they are only estimates
and their reliability is not precisely known.
The UK is well placed to contribute to many of the
priority research areas that need additional funding,
given particular focuses on preclinical science as well as
operational and implementation research. However,
there is a need for funders in other countries to provide
similar and detailed information on funded studies, and
so build a global research funding database. This could
be used for analytical work to identify gaps in research
funding, reduce unnecessary duplication of research
investments, prioritise health and social policy decisions
and help inform resource allocation for global research
priorities.
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